Abstract
Verbal memory is impaired in neurological and psychiatric conditions and provides one of the main targets of intervention. Specifically, this cognitive domain has been shown to provide a major determinant of outcome in schizophrenia and mood disorders. Therefore, verbal memory disturbances should be focused in the development of novel pharmacological and psychosocial therapeutics. Effective integration between preclinical and clinical studies should provide a key to the pursuit of drugs enhancing verbal memory.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bourne C, Aydemir O, Balanza-Martinez V, Bora E, Brissos S, Cavanagh JT, Clark L, Cubukcuoglu Z, Dias VV, Dittmann S, Ferrier IN, Fleck DE, Frangou S, Gallagher P, Jones L, Kieseppa T, Martinez-Aran A, Melle I, Moore PB, Mur M, Pfennig A, Raust A, Senturk V, Simonsen C, Smith DJ, Bio DS, Soeiro-de-Souza MG, Stoddart SD, Sundet K, Szoke A, Thompson JM, Torrent C, Zalla T, Craddock N, Andreassen OA, Leboyer M, Vieta E, Bauer M, Worhunsky PD, Tzagarakis C, Rogers RD, Geddes JR, Goodwin GM (2013) Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr Scand 128:149–162
Buchanan RW, Conley RR, Dickinson D, Ball MP, Feldman S, Gold JM, McMahon RP (2008) Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 165:82–89
Burdick KE, Goldberg TE, Cornblatt BA, Keefe RS, Gopin CB, Derosse P, Braga RJ, Malhotra AK (2011) The MATRICS consensus cognitive battery in patients with bipolar I disorder. Neuropsychopharmacology 36:1587–1592
Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet IP, Prelipceanu D, Rybakowski JK, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rossler A, Kahn RS (2009) Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 166:675–682
Depp CA, Mausbach BT, Harmell AL, Savla GN, Bowie CR, Harvey PD, Patterson TL (2012) Meta-analysis of the association between cognitive abilities and everyday functioning in bipolar disorder. Bipolar Disord 14:217–226
Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, Woerner MG, Schooler NR, Kane JM, Robinson DG (2007) Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 64:1115–1122
Green MF, Kern RS, Braff DL, Mintz J (2000) Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull 26:119–136
Hagiwara H, Fujita Y, Ishima T, Kunitachi S, Shirayama Y, Iyo M, Hashimoto K (2008) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors. Eur Neuropsychopharmacol 18:448–454
Harvey PD (2009) Pharmacological cognitive enhancement in schizophrenia. Neuropsychol Rev 19:324–335
Harvey PD, Raykov T, Twamley EW, Vella L, Heaton RK, Patterson TL (2011) Validating the measurement of real-world functional outcomes: phase I results of the VALERO study. Am J Psychiatry 168:1195–1201
Hellvin T, Sundet K, Simonsen C, Aminoff SR, Lagerberg TV, Andreassen OA, Melle I (2012) Neurocognitive functioning in patients recently diagnosed with bipolar disorder. Bipolar Disord 14:227–238
Higuchi Y, Sumiyoshi T, Kawasaki Y, Matsui M, Arai H, Kurachi M (2008) Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300. Schizophr Res 101:320–330
Hill SK, Reilly JL, Keefe RS, Gold JM, Bishop JR, Gershon ES, Tamminga CA, Pearlson GD, Keshavan MS, Sweeney JA (2013) Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) Study. Am J Psychiatry 170:1275–1284
Horiguchi M, Meltzer HY (2012) The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition deficits in rats. Psychopharmacology (Berl) 221:205–215
Horiguchi M, Hannaway KE, Adelekun AE, Jayathilake K, Meltzer HY (2012) Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist. Neuropsychopharmacology 37:2175–2183
Keefe RS, Fenton WS (2007) How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophr Bull 33:912–920
Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L (2004) The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 68:283–297
Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64:633–647
Leifker FR, Patterson TL, Heaton RK, Harvey PD (2011) Validating measures of real-world outcome: the results of the VALERO expert survey and RAND panel. Schizophr Bull 37:334–343
Maruff P, Thomas E, Cysique L, Brew B, Collie A, Snyder P, Pietrzak RH (2009) Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol 24:165–178
Matsumoto J, Uehara T, Urakawa S, Takamura Y, Sumiyoshi T, Suzuki M, Ono T, Nishijo H (2014) 3D video analysis of the novel object recognition test in rats. Behav Brain Res 272:16–24
Meltzer HY, Sumiyoshi T (2003) Atypical antipsychotic drugs improve cognition in schizophrenia. Biol Psychiatry 53:265–267, author reply 267–268
Meltzer HY, Horiguchi M, Massey BW (2011) The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology (Berl) 213:289–305
Michalopoulou PG, Lewis SW, Wykes T, Jaeger J, Kapur S (2013) Treating impaired cognition in schizophrenia: the case for combining cognitive-enhancing drugs with cognitive remediation. Eur Neuropsychopharmacol 23:790–798
Nagai T, Murai R, Matsui K, Kamei H, Noda Y, Furukawa H, Nabeshima T (2009) Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology (Berl) 202:315–328
Nuechterlein KH, Green MF (2006) MATRICS consensus cognitive battery. MATRICS Assessment, Los Angeles, CA
Parkin AJ (1999) Memory: a guide for professionals. Wiley, West Sussex
Sumiyoshi T (2015) Cognitive impairment in schizophrenia. In: Stolerman I, Price LH (eds) Encyclopedia of Psychopharmacology, 2nd edn. Springer, New York
Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Uehara T, Kurachi M, Meltzer HY (2000) Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia [letter]. J Clin Psychopharmacol 20:386–388
Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, Sumiyoshi C, Jayathilake K, Meltzer HY (2001a) Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 158:1722–1725
Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Kurachi M, Uehara T, Sumiyoshi S, Sumiyoshi C, Meltzer HY (2001b) The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol Psychiatry 49:861–868
Sumiyoshi C, Sumiyoshi T, Roy A, Jayathilake K, Meltzer HY (2006a) Atypical antipsychotic drugs and organization of long-term semantic memory: multidimensional scaling and cluster analyses of category fluency performance in schizophrenia. Int J Neuropsychopharmacol 9:677–683
Sumiyoshi T, Higuchi Y, Kawasaki Y, Matsui M, Kato K, Yuuki H, Arai H, Kurachi M (2006b) Electrical brain activity and response to olanzapine in schizophrenia: a study with LORETA images of P300. Prog Neuropsychopharmacol Biol Psychiatry 30:1299–1303
Sumiyoshi T, Higuchi Y, Itoh T, Matsui M, Arai H, Suzuki M, Kurachi M, Sumiyoshi C, Kawasaki Y (2009) Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a three-dimensional analysis with sloreta. Psychiatry Res 172:180–183
Sumiyoshi T, Higuchi Y, Itoh T, Kawasaki Y (2011) Electrophysiological imaging evaluation of schizophrenia and treatment response. In: Risner MS (ed) Handbook of schizophrenia spectrum disorders, vol 3. Springer, New York
Sumiyoshi T, Higuchi Y, Uehara T (2013) Neural basis for the ability of atypical antipsychotic drugs to improve cognition in schizophrenia. Front Behav Neurosci 7:140
Torres IJ, DeFreitas CM, DeFreitas VG, Bond DJ, Kunz M, Honer WG, Lam RW, Yatham LN (2011) Relationship between cognitive functioning and 6-month clinical and functional outcome in patients with first manic episode bipolar I disorder. Psychol Med 41:971–982
Tulving EC, Fergus IM (2000) The Oxford handbook of memory. Oxford University Press, Oxford
Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005) A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8:457–472
Woodward ND, Purdon SE, Meltzer HY, Zald DH (2007) A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res 89:211–224
Yatham LN, Torres IJ, Malhi GS, Frangou S, Glahn DC, Bearden CE, Burdick KE, Martinez-Aran A, Dittmann S, Goldberg JF, Ozerdem A, Aydemir O, Chengappa KN (2010) The International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC). Bipolar Disord 12:351–363
Acknowledgment
This work was supported by grants-in-aid for Scientific Research from Japan Society for the Promotion of Science (No. 26461761), Health and Labour Sciences Research Grants for Comprehensive Research on Disability, Health, and Welfare (H24-Seishin-Ippan-002 and H26-Seishin-Ippan-011), and Intramural Research Grant for Neurological and Psychiatric Disorders of NCNP.
The author thanks Drs. Herbert Y. Meltzer, Philip D. Harvey, Richard Keefe, and Sohee Park for the discussions.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Sumiyoshi, T. (2015). Verbal Memory. In: Kantak, K., Wettstein, J. (eds) Cognitive Enhancement. Handbook of Experimental Pharmacology, vol 228. Springer, Cham. https://doi.org/10.1007/978-3-319-16522-6_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-16522-6_8
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-16521-9
Online ISBN: 978-3-319-16522-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)